Article info
PDFClinical and epidemiological research
Extended report
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
- Correspondence to Jürgen Braun, Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, D-44652 Herne, Germany; j.braun{at}rheumazentrum-ruhrgebiet.de
Citation
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Publication history
- Accepted August 27, 2011
- First published October 19, 2011.
Online issue publication
February 27, 2024
Article Versions
- Previous version (27 February 2024).
- Previous version (27 February 2024).
- You are viewing the most recent version of this article.
Web Only Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl